Akero Therapeutics

Youtube Subscribe

Open: 52.07 Close: 53.24 Change: 1.17

Are you looking for information about Akero Therapeutics? We programmed an AI to summarize it for you.

How much time have you spent trying to decide whether investing in Akero Therapeutics? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Akero Therapeutics are: …

Concept Map

Semantic Network

Stock Summary

Akero Therapeutics, Inc. engages in the development of transformational treatments for patients with serious metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc..

Today's Summary

Akero Therapeutics is a clinical-stage pharmaceutical company that develops treatments for non-alcoholic steatohepatitis (NASH) Wall Street Analysts think 29.22% in AkeroTherapeutics, Inc. Average price target hints at a 42.6% upside potential.

Today's News

Akero Therapeutics is a clinical-stage pharmaceutical company that develops treatments for non-alcoholic steatohepatitis (NASH) Yahoo! Finance. principal financial group inc. increases stake in Akero therapeutics, inc. and industry insiders express confidence in innovative metabolic disease treatment. Wall Street Analysts think 29.22% in Akero Therapeutics, Inc. (AKRO) Average price target hints at a 42.6% upside potential. Avidity Partners Management LP grew its position in Akero Therapeutics by 22.5% during the 4th quarter. Alkeon Capital Management LLC boosted its stake in shares of Akero Therapeutics by 2.6%. Director Pamela Sue Passman Sells 5,649 Shares of Stock Akero. Director Andrew Cheng sells 25,000 shares. Akero Therapeutics is a clinical-stage company developing treatments for patients with serious metabolic diseases marked by high unmet medical need. Efruxifermin (EFX), formerly known as AKR-001, is Akeros lead product candidate.

Stock Profile

"Akero Therapeutics, Inc., a clinical-stage company, engages in the development of transformational treatments for patients with serious metabolic diseases, including non-alcoholic steatohepatitis (NASH), a disease without any approved therapies. Its lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. The company is also conducting a Phase 2b clinical trial to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California."

Keywords

This document will help you to evaluate Akero Therapeutics without reading an infinite amount of sources. Relying only on stock quotes or prices to make investment decisions is a mistake. Analyzing and observing stock charts, highs and lows and other numerical data does not allow to evaluate the real value of a company. Stock quotes and prices are the result of underlying characteristics of a company and of events and news happening around them. For this reason, investing must be based on information, not numbers. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Akero Therapeutics are: Akero, Therapeutics, treatment, clinicalstage, company, develop, inc, and the most common words in the summary are: akero, therapeutic, liver, inc, patient, nash, news, . One of the sentences in the summary was: Average price target hints at a 42.6% upside potential.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #akero #therapeutic #liver #inc #patient #nash #news.

Read more →

Youtube Subscribe

---